Key result
Anti-inflammatory therapies show inconsistent CAD benefit, with major cardiovascular events reductions largely limited to colchicine and canakinumab.
Why the study?
Pro-inflammatory cytokines play an important role in multiple facets of CAD, prompting a review of key RCT data on anti-inflammatory drugs for improving CAD outcomes.
Do anti-inflammatory therapies improve clinical and radiographic outcomes (including secondary prevention of MACE, radiographic progression of CAD, and acute reperfusion injury) compared to placebo in patients with coronary artery disease?
Systematic Review
Do anti-inflammatory therapies improve clinical and radiographic outcomes (including secondary prevention of MACE, radiographic progression of CAD, and acute reperfusion injury) compared to placebo in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
While most anti-inflammatory agents failed to improve coronary artery disease outcomes in randomized trials, targeted inhibition of the NLRP3-IL1β-IL6-CRP pathway with colchicine, canakinumab, or peri-reperfusion tocilizumab demonstrated clinical and myocardial salvage benefits.
AIMS: Pro-inflammatory cytokines play an important role in multiple facets of coronary artery disease (CAD), from endothelial dysfunction to plaque development and rupture to reperfusion injury post-revascularisation. We aimed to identify and present key data from randomized controlled trials (RCTs) which investigate anti-inflammatory drugs with the goal of improving outcomes associated with CAD. METHODS AND RESULTS: We searched for placebo-controlled RCTs across three databases (Cochrane Library, PubMed, and ClinicalTrials.gov) using the terms "anti-inflammatory" and "coronary artery disease" as well as variants. Thirty-three studies were identified and categorized as: (a) secondary prevention of major adverse cardiovascular events (MACE), (b) secondary prevention of radiographic evidence of CAD, and (c) reduction in reperfusion injury when administered during reperfusion. Seven trials demonstrated a reduction in CAD, including five phase III trials for secondary prevention of MACE. CONCLUSION: The majority of anti-inflammatory therapies did not show improved outcomes across a variety of endpoints. However colchicine and canakinumab have shown benefit in reducing MACE in phase III trials, while tocilizumab improved myocardial salvage index when administered peri-reperfusion. These findings suggest that the NLRP3-IL1β-IL6-CRP pathway may represent a promising therapeutic target and an important focus for future research in CAD prevention, particularly in patients with high residual inflammatory risk.
No takes yet. Share an insight, caveat, or question.
Courcy et al. (2026) conducted a systematic review in Coronary artery disease. Anti-inflammatory therapies (including colchicine, canakinumab, tocilizumab, darapladib, succinobucol, losmapimod, methotrexate, salsalate, celecoxib, MEDI6570, N-acetylcysteine, everolimus, and pentoxifylline) vs. Placebo was evaluated on Secondary prevention of major adverse cardiovascular events (MACE), radiographic evidence of CAD, and reduction in acute reperfusion injury. Among 28 reviewed RCTs of anti-inflammatory therapies in CAD, only 7 trials showed benefit, with colchicine and canakinumab reducing major cardiovascular events in 5 phase III trials.
Synapse has enriched 10 related papers. Consider them for comparative context: